View Older Stories View More Recent Stories

Feb 1, 2022 07:00AM AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
Jan 28, 2022 07:00AM AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
Jan 27, 2022 07:00AM AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
Jan 6, 2022 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2022 07:01AM AVROBIO Inc. (AVRO) deprioritizing its Fabry disease program
Jan 4, 2022 07:00AM AVROBIO Reprioritizes Pipeline Programs
Dec 7, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 24, 2021 07:01AM AVROBIO Inc. (AVRO) Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
Nov 24, 2021 07:00AM AVROBIO Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1
Nov 9, 2021 07:00AM AVROBIO to Present at Two Upcoming Investor Conferences in November
Nov 8, 2021 07:00AM AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference
Nov 5, 2021 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 4, 2021 07:00AM AVROBIO Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 3, 2021 07:00AM AVROBIO Inc. (AVRO) Receives FDA Rare Pediatric Disease Designation for AVR-RD-05
Nov 3, 2021 07:00AM AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome
Oct 26, 2021 07:10AM AVROBIO Inc. (AVRO) Appoints Essra Ridha as Chief Medical Officer
Oct 26, 2021 07:00AM AVROBIO Announces the Appointment of Essra Ridha, M.D., MRCP, FFPM, as Chief Medical Officer
Oct 20, 2021 07:00AM AVROBIO to Present at the Jefferies Virtual Gene Therapy/Editing Summit
Oct 19, 2021 07:11AM AVROBIO Inc. (AVRO) Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
Oct 19, 2021 07:00AM AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1
Oct 6, 2021 07:00AM AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress
Oct 5, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 3, 2021 04:01PM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2021 07:00AM AVROBIO to Participate at Four Upcoming Investor Conferences
Aug 5, 2021 07:00AM AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update
Aug 4, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 2, 2021 07:00AM AVROBIO to Present at Two Upcoming Investor Conferences in August
Jul 8, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 10, 2021 07:00AM AVROBIO to Present at the JMP Securities Life Sciences Conference
Jun 4, 2021 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 13, 2021 07:00AM AVROBIO Reports First Quarter 2021 Financial Results and Provides Business Update
May 6, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 3, 2021 07:08AM AVROBIO Inc. (AVRO) Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
May 3, 2021 07:00AM AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
Apr 27, 2021 04:46PM AVROBIO Inc. (AVRO) to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
Apr 27, 2021 04:30PM AVROBIO to Present Clinical and Preclinical Data at the ASGCT 24th Annual Meeting
Apr 6, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 18, 2021 07:00AM AVROBIO Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update
Mar 5, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2021 07:03AM AVROBIO Inc. (AVRO) Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis
Mar 1, 2021 07:00AM AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑04, an Investigational Gene Therapy for Cystinosis
Feb 25, 2021 07:00AM AVROBIO to Present at Three Upcoming Investor Conferences in March
Feb 8, 2021 07:00AM AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial
Feb 5, 2021 04:05PM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 1, 2021 07:00AM AVROBIO Announces Multiple Clinical Data Presentations, Posters and Events at 17th Annual WORLDSymposium™ 2021
Jan 22, 2021 07:00AM AVROBIO to Present at the Cowen 2021 Gene Therapy: CMC & Regulatory Summit
Jan 19, 2021 07:00AM AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer
Jan 8, 2021 07:00AM AVROBIO to Present at the ICR Conference 2021
Jan 7, 2021 07:00AM AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 4, 2020 07:00AM AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories